Which Small Cap ETF Is the Better Buy in 2026? iShares and JPMorgan Have Compelling Offerings
ISCB offers ultra-low costs and 1,500+ holdings for diversification, while BBSC concentrates on fewer names with higher recent returns.
GH - Guardant Health, Inc.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$155.79
DETAILS
HIGH:
$200.00
LOW:
$115.00
MEDIAN:
$155.00
CONSENSUS:
$155.79
DOWNSIDE:
0.24%
Stock News
UnitedHealth Group Now Covers Guardant Health's Shield Blood Test for Colorectal Cancer Screening
PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced its Shield™ blood test for colorectal cancer screening (CRC) is now covered for eligible UnitedHealth Group (UHG) members1, making it the first major commercial insurer to provide coverage for adults 45 or older amid rising CRC rates for adults under 652 and mortality for younger adults as the leading cause of cancer death for those under 50.3 Shield is the first and onl.
State Street SPDR Small Cap ETF Outpaces iShares on Returns
Explore how portfolio size and sector exposure differ between these two small-cap ETFs, each offering unique advantages for investors.
Living Longer Is Big Business. These Stocks Will Benefit.
TD Cowen analysts estimate that the total addressable market for longevity healthcare exceeds $250 billion.
Gamehost Receives Final Court Order Authorizing Sale to Pure Casino Entertainment
Not intended for distribution to U.S. newswire services or for dissemination in the U.S. Red Deer, Alberta--(Newsfile Corp. - June 15, 2026) - Gamehost Inc. (TSX: GH) ("Gamehost") announced that the Court of King's Bench of Alberta has granted the final order authorizing Gamehost to proceed with its previously announced transaction with Pure Casino Entertainment Limited Partnership ("Pure") pursuant to which a subsidiary of Pure will acquire all of the outstanding common shares of Gamehost (the "Gamehost Shares") for $13.65 in cash per share (the "Transaction"). The Transaction was approved at a special meeting of the shareholders of Gamehost (the "Gamehost Shareholders") held on June 11, 2026.
Gamehost Shareholders Approve Sale to Pure Casino Entertainment
Red Deer, Alberta--(Newsfile Corp. - June 12, 2026) - Gamehost Inc. (TSX: GH) ("Gamehost") announced that its shareholders (the "Gamehost Shareholders") have approved its previously announced transaction with Pure Casino Entertainment Limited Partnership ("Pure") pursuant to which a subsidiary of Pure will acquire all of the outstanding common shares of Gamehost (the "Gamehost Shares") for $13.65 in cash per share (the "Transaction"). The Transaction was approved at a special meeting of the Gamehost Shareholders held on June 11, 2026 (the "Meeting").
Guardant Health Announces FDA Approval of Guardant360 CDx as Companion Diagnostic for Boehringer Ingelheim's HERNEXEOS®
PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that the U.S. Food and Drug Administration (FDA) has approved Guardant360® CDx as a companion diagnostic (CDx) for Boehringer Ingelheim's HERNEXEOS® (zongertinib tablets), the first targeted therapy for adults with HER2 (ERBB2)-mutant advanced non-small cell lung cancer (NSCLC) as an initial treatment option. The approval enables Guardant360 CDx, a liquid biopsy test tha.
Here's Why This Colon Cancer Testing Biotech Is A Mutual Fund Favorite
This biotech has a one-of-a-kind colon cancer blood test. Shares broke out of a base on recent news.
Here Are Tuesday’s Top Wall Street Analyst Research Calls: CoreWeave, Danaher, Hewlett Packard Enterprise, Intuit, Knight-Swift, Meta Platforms, Starwood Property Trust, Tripadvisor, and More
Pre-Market Stock Futures: Futures are trading lower on Tuesday, but the technology tsunami continued on Monday, as all major indices dipped into the red early on news that Iran was halting the peace negotiations and would block the Strait of Hormuz. But that sell-off lasted until about noon, before a big reversal, which, by that... Here Are Tuesday's Top Wall Street Analyst Research Calls: CoreWeave, Danaher, Hewlett Packard Enterprise, Intuit, Knight-Swift, Meta Platforms, Starwood Property Trust, Tripadvisor, and More
Guardant Health and Collaborators to Present 38 Abstracts Highlighting Breadth and Expanded Clinical Utility of Guardant Liquid Biopsy Tests Powered by InfinityAI at 2026 ASCO Annual Meeting
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company and its research collaborators will present 38 abstracts,
Guardant Health and Collaborators to Present 38 Abstracts Highlighting Breadth and Expanded Clinical Utility of Guardant Liquid Biopsy Tests Powered by InfinityAI at 2026 ASCO Annual Meeting
PALO ALTO, Calif.--(BUSINESS WIRE)---- $GH--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company and its research collaborators will present 38 abstracts, as well as one oral presentation in partnership with Pfizer, showcasing advances in methylation-based tumor classification and liquid biopsy technology at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois taking place May 29 – June 2, 2026. Key data that will be prese.
Guardant Health Is Poised To Break Out At The Open — Here's Why It Surged
Guardant Health stock spiked Wednesday after the American Cancer Society recommended its blood test as a screening tool for colon cancer.
American Cancer Society Recommends Guardant Health's Shield Blood Test in Updated Colorectal Cancer Screening Guidelines
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, announced that its FDA-approved Shield⢠blood test is now included in updated Ameri
American Cancer Society Recommends Guardant Health's Shield Blood Test in Updated Colorectal Cancer Screening Guidelines
PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, announced that its FDA-approved Shield™ blood test is now included in updated American Cancer Society (ACS) Colorectal Cancer (CRC) Screening Guidelines published today. The major screening guideline update recommends Shield as a choice for patients who decline or have not completed stool-based or visual examination screening tests. In an effort to address persistent screening gaps and.
Guardant Health Secures FDA Approval For Expanded Liquid Biopsy Test
The U.S. Food and Drug Administration (FDA) on Wednesday approved Guardant Health Inc.'s (NASDAQ:GH) Guardant360 Liquid CDx test, expanding the company's blood-based comprehensive genomic profiling capabilities for patients with advanced cancer.
Guardant Health Leaps On A Major Win In Cancer Detection; Will Shares Break Out?
The Food and Drug Administration approved Guardant Health's newest blood cancer test Wednesday, and the stock leaped to a three-month high.
FDA Approves New Guardant360 Liquid CDx, the Largest FDA-Approved Liquid Biopsy Panel with a 100x Expanded Footprint
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that the U.S. Food and Drug Administration (FDA) has approved Guardan
FDA Approves New Guardant360 Liquid CDx, the Largest FDA-Approved Liquid Biopsy Panel with a 100x Expanded Footprint
PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that the U.S. Food and Drug Administration (FDA) has approved Guardant360® Liquid CDx, advancing blood-based comprehensive genomic testing by integrating genomic and epigenomic insights and helping clinicians make better-informed treatment selection decisions for patients with advanced cancer. Guardant360 Liquid CDx is the largest FDA-approved liquid biopsy panel, assess.
Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that on April 21, 2026, the Compensation Committee of Guardant's Board of Directors approved the granting of restricted stock units (“RSUs”) representing 143,898 shares of its common stock to 267 new non-executive employees with a grant date of May 11, 2026 under the Guardant Health, Inc. 2023 Employment Inducement Incentive Award Plan (the “Inducement Plan”). The RSUs w.
Guardant Health: Reveal And Shield Driving The Next Growth Phase
Guardant Health, Inc. delivered strong results in the first quarter, with accelerating revenue growth supported by the MRD and screening businesses. GH's Quest Diagnostics partnership, product upgrades, and expanded reimbursement are set to sustain strong fundamentals and revenue diversification. While Guardant's losses are still sizeable, the company is on a clear path to profitability, driven by the scaling on the MRD and screening businesses.
Price Targets
Guardant Health price target raised to $200 from $160 at Evercore ISI
$200.00
(was $169.45)
Vijay Kumar
·
Evercore ISI
Guardant Health price target raised to $200 from $175 at Bernstein
$200.00
(was $170.77)
Eve Burstein
·
Bernstein
Guardant Health price target raised to $190 from $160 at BTIG
$190.00
(was $170.19)
BTIG
Guardant Health price target raised to $160 from $135 at Guggenheim
$160.00
(was $149.22)
Guggenheim
Guardant Health price target raised to $150 from $120 at Barclays
$150.00
(was $130.83)
UBS
RBC Capital Starts Guardant Health (GH) at Outperform, 'Underpenetrated Market'
$185.00
(was $130.90)
Dan Leonard
·
RBC Capital
Guardant Health price target raised to $175 from $135 at Mizuho
$175.00
(was $125.61)
Mizuho Securities
Goldman Sachs Starts Guardant Health (GH) at Buy
$165.00
(was $133.06)
Evie Koslosky
·
Goldman Sachs
Guardant Health upgraded to Outperform from In Line at Evercore ISI
$160.00
(was $129.14)
Evercore ISI
Guardant Health price target raised to $160 from $155 at BTIG
$160.00
(was $127.41)
BTIG
Guardant Health (GH) PT Raised to $155 at BTIG
$155.00
(was $118.95)
Mark Massaro
·
BTIG
TD Cowen Reiterates Buy Rating on Guardant Health (GH) Following G360 Liquid FDA Approval
$127.00
(was $119.33)
Piper Sandler
Guardant Health price target raised to $135 from $130 at Piper Sandler
$135.00
(was $96.71)
David Westenberg
·
Piper Sandler
Guardant Health price target lowered to $115 from $130 at Barclays
$115.00
(was $82.21)
Luke Sergott
·
Barclays
Guardant Health price target raised to $130 from $120 at Piper Sandler
$130.00
(was $94.42)
Piper Sandler
Guardant Health price target raised to $129 from $115 at Raymond James
$129.00
(was $97.49)
Raymond James
Guardant Health price target raised to $110 from $105 at Evercore ISI
$110.00
(was $106.84)
Evercore ISI
Guardant Health price target raised to $145 from $140 at BTIG
$145.00
(was $106.38)
BTIG
Guardant Health price target raised to $130 from $120 at Stifel
$130.00
(was $106.38)
Stifel Nicolaus
Guardant Health price target raised to $135 from $125 at Canaccord
$135.00
(was $106.38)
Canaccord Genuity